Published June 1, 2005 | Version v1
Journal article

Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: A prospective study of 110 patients

  • 1. Department of Radiation, Polyclinique Courlancy, Reims (France) and Department of Neurosurgery, Centre Hospitalier Universitaire Reims, Reims (France)
  • 2. Department of Medical Information, Centre Hospitalier Universitaire Reims, Reims (France)
  • 3. Department of Endocrinology, Centre Hospitalier Universitaire Reims, Reims (France)
  • 4. Department of Neurosurgery, Centre Hospitalier Universitaire Reims, Reims (France)
  • 5. Department of Radiation, Polyclinique Courlancy, Reims (France)

Description

Purpose: To optimize and reduce the toxicity of pituitary adenoma irradiation by assessing the feasibility and effectiveness of fractionated stereotactic radiotherapy (FSR). Methods and Materials: Between 1990 and 1999, 110 consecutive patients, 47 with a functioning adenoma, were treated according to a strategy of either early surgery and FSR (n = 89) or FSR only (n = 21). Of the 110 patients, 75 had persistent macroscopic tumor and 47 persistent hormonal secretions; 15 were treated in the prophylactic setting. The linear accelerator-delivered dose was 50.4 Gy (5 x 1.8 Gy weekly), with a 2-mm safety margin. Results: After a minimal follow-up of 48 months, only 1 patient had developed progression. Of the 110 patients, 27 (36%) had a complete tumor response, 67 (89.3%) had an objective tumor response, 20 (42%) had a hormonal complete response, and 47 (100%) had a hormonal objective tumor response. The proportion of patients without a complete tumor response, objective tumor response, complete hormonal response, and objective hormonal response was 85.1%, 62%, 83%, and 59.3% at 4 years and 49.3%, 9%, 59.3%, and 10.6% at 8 years, respectively. The sole unfavorable predictive factor was preoperative SSE >20 mm for tumor response (p = 0.01) and growth hormone adenoma for the hormonal response (p <0.001). No late complications, except for pituitary deficiency, were reported, with a probability of requiring hormonal replacement of 28.5% and 35% at 4 and 8 years, respectively. Nonfunctioning status was the sole unfavorable factor (p = 0.0016). Conclusions: Surgery plus FSR is safe and effective. FSR focused to the target volume seems more suitable than standard radiotherapy, and standard fractionation reduces the risk of optic neuropathy sometimes observed after single-dose radiosurgery. Therefore, FSR allows us to consider combined transrhinoseptal surgery and early radiotherapy, with a curative goal without patient selection

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2004.09.058;
PII
S0360-3016(04)02702-6;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
62
Journal Issue
2
Journal Page Range
p. 333-341
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
37014446
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ADENOMAS; FRACTIONATION; IRRADIATION; PATIENTS; RADIATION DOSES; RADIOTHERAPY; SAFETY MARGINS; SECRETION; STH; SURGERY; TOXICITY
Descriptors DEC
CARCINOMAS; DISEASES; DOSES; HORMONES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; PEPTIDE HORMONES; PITUITARY HORMONES; PROTEINS; RADIOLOGY; SEPARATION PROCESSES; THERAPY

Optional Information

Copyright
Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.